Global Statistics

All countries
176,902,568
Confirmed
Updated on June 14, 2021 2:47 pm
All countries
159,306,835
Recovered
Updated on June 14, 2021 2:47 pm
All countries
3,822,523
Deaths
Updated on June 14, 2021 2:47 pm
Monday, June 14, 2021

Global Statistics

All countries
176,902,568
Confirmed
Updated on June 14, 2021 2:47 pm
All countries
159,306,835
Recovered
Updated on June 14, 2021 2:47 pm
All countries
3,822,523
Deaths
Updated on June 14, 2021 2:47 pm
Molderizer and Safe Shield

Mayo study finds COVID-19 antibody therapy safe, effective for organ transplant recipients

US Set To Reach 100 Million Vaccine Shots, But COVID-19 Cases Are Growing | TODAY

About: TODAY brings you the latest headlines and expert tips on money, health and parenting. We wake up every morning to give you and...

As US COVID-19 Death Toll Nears 600,000, Racial Gaps Persist | Chicago News

In this April 22, 2020, file photo, pallbearers, who were among only 10 allowed mourners, walk the casket for internment at the funeral...

Communication technology, study of collective behavior must be ‘crisis discipline,’ researchers argue

News releases June 14, 2021 Our ability to confront global crises,...

California Coronavirus Deaths: The Toll on Hispanic Americans

To a wide circle of friends and family, Jesse Ruby was the go-to guy.The father who would drop everything and drive across town...

Facts not Fear: Informing you about the coronavirus

11Alive will bring you context and perspective regarding. source


The study, published Thursday, June 10, in the journal Open Forum Infectious Disease describes the care of 73 solid organ transplant recipients patients given either the monoclonal antibody bamlanivimab made by Eli Lilly, or casirivimab-imdevimab combination marketed by Regeneron.

“Monoclonal antibody therapy is really important for the transplant population because they are less likely to develop their own immunity,” Mayo Clinic infectious diseases specialist and senior author Dr. Raymund Razonable said in a statement.

Among the study’s findings, though transplant recipients historically have elevated risk of poor outcomes with COVID-19, none of the patients treated died, required mechanical ventilation or experienced organ rejection. Only one of the patients needed to be admitted to the ICU.

Monoclonal antibody therapy for COVID-19 is one of a handful of treatments whose efficacy against the virus is well-established. The treatments are lab-engineered proteins designed to mimic natural antibodies targeting the spike proteins on SARS-CoV2.

Since being given an Emergency Use Authorization in November 2020, the infusions are used for newly diagnosed COVID-19 patients with elevated risk factors for poor outcomes.

Early treatment is critical, however, with patients receiving the infusions at dedicated COVID-19 monoclonal antibody treatment centers.

With the success of vaccination in reducing new case counts to levels not seen since the start of the pandemic, monoclonal antibody therapy for COVID-19 is increasingly of interest to those who cannot produce the needed antibodies in response to vaccination.

Research shows organ transplant recipients, who take anti-rejection drugs that inhibit their immune response, have only a 65% likelihood of developing immunity following COVID-19 vaccination, compared to 95% effectiveness for others.

“Vaccination is an option for immunocompromised, but they might not respond as well,” Razonable said. “If they develop COVID-19 we (now) know this is going to be an option for them.”

Further clouding the picture, concerns had existed that giving transplant recipients a therapy that initiates an immune response could increase the risk of organ rejection, as their body fights the donor organ along with spike protein.

“One of the concerns was that this is an antibody that promotes rejection,” Razonable said. “While that was of concern, we did not see that.”

Because organ recipients were not included in the studies that helped the therapies gain approval, it was not known if they could safely take the therapies. Researchers charted the outcomes in recipients of kidneys, livers, lungs, hearts and pancreas.

The patients had been five years out from the date of their transplant on average. All infusions were given at dedicated COVID-19 monoclonal antibody transfusion centers operated by Mayo Clinic.

The study was limited in that it was an observational case review which did not study a control population of transplant recipients who did not receive the therapies. Future research will look at the effectiveness of COVID-19 monoclonal antibody therapy in other immunocompromised populations, Rayzonable said.



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Popular

US Set To Reach 100 Million Vaccine Shots, But COVID-19 Cases Are Growing | TODAY

About: TODAY brings you the latest headlines and expert tips on money, health and parenting. We wake up every morning to give you and...

As US COVID-19 Death Toll Nears 600,000, Racial Gaps Persist | Chicago News

In this April 22, 2020, file photo, pallbearers, who were among only 10 allowed mourners, walk the casket for internment at the funeral...

Communication technology, study of collective behavior must be ‘crisis discipline,’ researchers argue

News releases June 14, 2021 Our ability to confront global crises,...

Related Articles

US Set To Reach 100 Million Vaccine Shots, But COVID-19 Cases Are Growing | TODAY

About: TODAY brings you the latest headlines and expert tips on money, health and parenting. We wake up every morning to give you and...

As US COVID-19 Death Toll Nears 600,000, Racial Gaps Persist | Chicago News

In this April 22, 2020, file photo, pallbearers, who were among only 10 allowed mourners, walk the casket for internment at the funeral...

Communication technology, study of collective behavior must be ‘crisis discipline,’ researchers argue

News releases June 14, 2021 Our ability to confront global crises,...